Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2NETWORK 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Neuroendocrine Tumors 5Neoplasms 5Carcinoid Tumor 5Gastro-enteropancreatic neuroendocrine tumor 3Diarrhea 3Carcinoma 3Acromegaly 3Colorectal Neoplasms 2Thymoma 1Rectal Neoplasms 1Pituitary Neoplasms 1Peritoneal Neoplasms 1Neoplasm Metastasis 1Malignant Carcinoid Syndrome 1Intestinal Obstruction 1Disease 1Colonic Neoplasms 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Neoplasms 1Adenoma, Islet Cell 1

Interventions

Bevacizumab 187Fluorouracil 150Leucovorin 135Cetuximab 127Irinotecan 114Oxaliplatin 108pembrolizumab 96Capecitabine 82IFL protocol 53Panitumumab 43Nivolumab 43regorafenib 42Folfox protocol 39Gemcitabine 30trifluridine tipiracil drug combination 27Cisplatin 24Carboplatin 24atezolizumab 23Pemetrexed 20Paclitaxel 20Drug Therapy 20130-nm albumin-bound paclitaxel 17Trastuzumab 14encorafenib 13Trifluridine 13Ipilimumab 13HMPL-013 13tislelizumab 12spartalizumab 11Docetaxel 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Colorectal Neoplasms × Octreotide × Clear all
NCT00006269 2012-05-25

Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

Novartis

Phase 3 Terminated
89 enrolled
Gastrointestinal

Colonic Neoplasms, Diarrhea, Rectal Neoplasms, Colorectal Neoplasms

NCT00050635 2009-11-19

STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea

Novartis

Phase 4 Completed
150 enrolled
Gastrointestinal

Diarrhea, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡